I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
ImmunityBio Inc. (NASDAQ: IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at ...
A new study analyzing the immune response to COVID-19 in a Catalan cohort of health workers sheds light on an important question: does it matter whether a person was first infected or first vaccinated ...
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision ...
Morning Overview on MSN
Scientists find a protein that may rejuvenate aging immunity
Scientists are closing in on a deceptively simple idea with radical implications: that a single protein signal in the blood can push aging immune cells to behave as if they were young again. Instead ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival ...
Immunitybio Inc ( (IBRX)) has released its Q3 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors. ImmunityBio, Inc. is a biotechnology company focused on ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline.
A mechanism of antiviral immunity in bacteria has been characterized. A research team from Umeå University (Sweden) has uncovered a mechanism for how bacteria build up antiviral immunity against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback